Repligen | RGEN - 税前利润

金融业

USD

USD 2.93B

现金及等价物

USD 582.65M

USD 85.97M

USD 1.16B

USD 126.21M

USD 546.59M

USD 19.98M

USD 40.01M

1.78K

EPS每股收益

USD 0.48

股本和储备

USD 2.11B

USD 108.28M

债务利息支出

USD 5.58M

USD 7.31M

USD 546.59M

USD 6.42B

USD 8.33M

USD 174.27M

USD 19.98M

普通股股本

USD 56.4M

109.48

USD 19.11M

USD 194M

销售和管理费用

USD 76.54M

USD 179.26M

贸易债权人

USD 34.66M

应收帐款人

USD 151.55M

	税前利润	更改		日
Agilent	USD 364M		78M	2025-12
Align Technology	USD 148.89M		27.71M	2026-03
Bio Techne	USD 50.78M		34.21M	2025-12
BioMarin Pharmaceutical	USD 141.2M		168.36M	2026-03
Bristol-Myers Squibb	USD 1.47B		1.64B	2025-12
Bruker	USD 68.2M		140.8M	2025-12
Charles River Laboratories	USD -294.1M		464.13M	2025-12
Danaher	USD 1.24B		138M	2026-03
Dentsply International	USD -42M		105M	2026-03
General Electric Aerospace	USD 2.2B		654M	2026-03
Henry Schein	USD 150M		17M	2026-03
Illumina	USD 157M		220M	2026-03
IQVIA Holdings	USD 6.22B		5.68B	2026-03
Mettler Toledo International	USD 329.07M		59.84M	2025-12
Myriad Genetics	USD 4.6M		3.4M	2025-12
OraSure Technologies	USD -18.43M		5.14M	2025-12
Pacific Biosciences Of California	USD -40.17M		2.55M	2025-12
Pfizer	USD 5.18B		6.82B	2026-03
Repligen	USD 19.11M		2M	2025-12
Revvity	USD 91.56M		35.88M	2025-12
Standard Biotools	USD -22.03M		10.87M	2025-12
Thermo Fisher Scientific	USD 2.12B		295M	2025-12
Waters	USD 264.18M		94.06M	2025-12
West Pharmaceutical Services	USD 161.5M		8.6M	2025-12